GENFLEET-B (02595) Clarifies No Connection to Rev Med's Legal Dispute

Stock News04-28 12:40

GENFLEET-B (02595) has issued an announcement stating that the company recently noted several reports concerning a letter sent by Revolution Medicines Inc. ("Rev Med") to a third-party company regarding a dispute over RAS inhibitor patents and trade secrets. The company hereby clarifies and emphasizes that the entities, products, and matters in dispute mentioned in Rev Med's letter are entirely unrelated to GENFLEET. The company's Pan RAS inhibitor, GFH276, possesses completely independent and original intellectual property rights, with no risk of similar infringement or trade secret disputes. GENFLEET has established a comprehensive global patent portfolio for its Pan RAS inhibitor program. A patent covering the compound structure of GFH276 was officially published on March 6, 2025, with an expected protection period lasting until 2044.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133388661?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-28 12:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133388661","market":"sg","top_or_hot":-1,"title":"GENFLEET-B (02595) Clarifies No Connection to Rev Med's Legal Dispute","media":"Stock News","content":"<p>GENFLEET-B (02595) has issued an announcement stating that the company recently noted several reports concerning a letter sent by Revolution Medicines Inc. (\"Rev Med\") to a third-party company regarding a dispute over RAS inhibitor patents and trade secrets. The company hereby clarifies and emphasizes that the entities, products, and matters in dispute mentioned in Rev Med's letter are entirely unrelated to GENFLEET. The company's Pan RAS inhibitor, GFH276, possesses completely independent and original intellectual property rights, with no risk of similar infringement or trade secret disputes. GENFLEET has established a comprehensive global patent portfolio for its Pan RAS inhibitor program. A patent covering the compound structure of GFH276 was officially published on March 6, 2025, with an expected protection period lasting until 2044.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENFLEET-B (02595) Clarifies No Connection to Rev Med's Legal Dispute</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENFLEET-B (02595) Clarifies No Connection to Rev Med's Legal Dispute\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-28 12:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENFLEET-B (02595) has issued an announcement stating that the company recently noted several reports concerning a letter sent by Revolution Medicines Inc. (\"Rev Med\") to a third-party company regarding a dispute over RAS inhibitor patents and trade secrets. The company hereby clarifies and emphasizes that the entities, products, and matters in dispute mentioned in Rev Med's letter are entirely unrelated to GENFLEET. The company's Pan RAS inhibitor, GFH276, possesses completely independent and original intellectual property rights, with no risk of similar infringement or trade secret disputes. GENFLEET has established a comprehensive global patent portfolio for its Pan RAS inhibitor program. A patent covering the compound structure of GFH276 was officially published on March 6, 2025, with an expected protection period lasting until 2044.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159938","symbol_name":"医药","start_time":0,"source_url":"","article_id":"1133388661","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133388661","pubTimestamp":1777351214,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GENFLEET-B (02595) has issued an announcement stating that the company recently noted several reports concerning a letter sent by Revolution Medicines Inc. (\"Rev Med\") to a third-party company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","BK1515":"抗疫概念","09939":"开拓药业-B","BK1161":"生物科技","BK1574":"生物医药B类股","02595":"劲方医药-B"},"translate_title":"GENFLEET-B(02595)澄清与Rev Med法律纠纷无关","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"02595":1,"09939":1},"content_text":"GENFLEET-B (02595) has issued an announcement stating that the company recently noted several reports concerning a letter sent by Revolution Medicines Inc. (\"Rev Med\") to a third-party company regarding a dispute over RAS inhibitor patents and trade secrets. The company hereby clarifies and emphasizes that the entities, products, and matters in dispute mentioned in Rev Med's letter are entirely unrelated to GENFLEET. The company's Pan RAS inhibitor, GFH276, possesses completely independent and original intellectual property rights, with no risk of similar infringement or trade secret disputes. GENFLEET has established a comprehensive global patent portfolio for its Pan RAS inhibitor program. A patent covering the compound structure of GFH276 was officially published on March 6, 2025, with an expected protection period lasting until 2044.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133388661","isCrawlerRequest":true}